The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers

Noehr-Jensen, Lene; Damkier, Per; Bidstrup, Tanja Busk; Pedersen, Robert Smith; Nielsen, Flemming; Brøsen, Kim

doi:10.1007/s00228-006-0139-6

Cited by 17 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Loratidine) Noehr-Jensen et al (2006) reported that the oral bioavailability of loratadine from the chewing gum formulation was 3-fold higher compared with tablet and smelt tablet formulations. This was attributed to the fact that buccal absorption from the chewing gum formulation by-passes the traditional first pass effect from the gastrointestinal tract absorption.…”

Section: Selected Interesting Applications Of Salivary Analysismentioning

confidence: 98%

Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives

Mullangi

Agrawal

Srinivas³

2008

Biomedical Chromatography

View full text Add to dashboard Cite

The use of saliva for measuring xenobiotic concentrations has been practiced for a number of years. While the use of saliva has been generally reserved for the analysis of diagnostic and forensic/toxicology samples, attempts have been made to further enhance the value of saliva as an alternate matrix to those of plasma and serum. It is understood that saliva represents a handy tool for therapeutic drug monitoring (TDM) as it offers certain distinctive advantages. This scope of this review encompasses the following: (a) a comprehensive view of saliva as an alternate matrix for either plasma or serum to understand the pharmacokinetic/pharmacodynamic (PK/PD) characteristics; (b) an account of the factors contributing to the observed variability in salivary monitoring; (c) a tabular compilation of diverse case studies of xenobitoics belonging to different therapeutic classes with emphasis on assay methodology and applicable analytical/biopharmaceutical/pharmacokinetic findings; (d) relevant thoughts on assay procedures as they relate to salivary monitoring; and (e) some representative case studies highlighting the new thinking on the use of saliva outside of traditional TDM. Overall, based on the review, saliva represents a valuable TDM tool for a number of xenobiotics. While parent compound and phase I metabolite(s) for many xenobiotics have been generally quantifiable in saliva, phase II metabolites have not generally been detected in saliva. Therefore saliva samples could also be used to answer some specific PK/PD questions during the drug development process, if applicable. However, the development and validation of the assay in saliva needs to be carried out carefully with particular focus on proper sample collection, processing and storage to ensure the stability of the xenobiotics and with the same rigor as applied to plasma, serum and urine matrices.

show abstract

Section: Selected Interesting Applications Of Salivary Analysismentioning

confidence: 98%

Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives

Mullangi

Agrawal

Srinivas³

2008

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetic results provide proof of concept that Loratadine formulated as a buccoadhesive wafer results in a statistically significant increase in its bioavailability, probably due to absorbed through buccal mucosa and reduction of first-pass metabolism (Noehr-Jensen et al, 2006).…”

Section: Pharmacokinetic Studymentioning

confidence: 56%

Comparative study on the predictability of statistical models (RSM and ANN) on the behavior of optimized buccoadhesive wafers containing Loratadine and their in vivo assessment

Chakraborty

Parcha²,

Chakraborty

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

Objective: Buccoadhesive wafer dosage form containing Loratadine is formulated utilizing Formulation by Design (FbD) approach incorporating sodium alginate and lactose monohydrate as independent variable employing solvent casting method. Methods: The wafers were statistically optimized using Response Surface Methodology (RSM) and Artificial Neural Network algorithm (ANN) for predicting physicochemical and physico-mechanical properties of the wafers as responses. Morphologically wafers were tested using SEM. Quick disintegration of the samples was examined employing Optical Contact Angle (OCA). Results: The comparison of the predictability of RSM and ANN showed a high prognostic capacity of RSM model over ANN model in forecasting mechanical and physicochemical properties of the wafers. The in vivo assessment of the optimized buccoadhesive wafer exhibits marked increase in bioavailability justifying the administration of Loratadine through buccal route, bypassing hepatic first pass metabolism.

show abstract

“…Earlier reports had revealed that formulation of Loratadine as a medicated chewing gum results in an almost threefold increase in relative bioavailability. This is due to the fact that approximately 40% of the absorbed Loratadine was absorbed via the oral mucosa and thereby bypassing first-pass metabolism [6]. Hence, it is an attempt to prepare pharmaceutical wafers of Loratadine with an aim to lessen the lag time and enhance the onset of action.…”

Section: Introductionmentioning

confidence: 99%

Design Expert Supported Mathematical Optimization and Predictability Study of Buccoadhesive Pharmaceutical Wafers of Loratadine

Chakraborty

Dey

Parcha³

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Objective. The objective of this work encompasses the application of the response surface approach in the development of buccoadhesive pharmaceutical wafers of Loratadine (LOR). Methods. Experiments were performed according to a 32 factorial design to evaluate the effects of buccoadhesive polymer, sodium alginate (A), and lactose monohydrate as ingredient, of hydrophilic matrix former (B) on the bioadhesive force, disintegration time, percent (%) swelling index, and time taken for 70% drug release (t 70%). The effect of the two independent variables on the response variables was studied by response surface plots and contour plots generated by the Design-Expert software. The desirability function was used to optimize the response variables. Results. The compatibility between LOR and the wafer excipients was confirmed by differential scanning calorimetry, FTIR spectroscopy, and X-ray diffraction (XRD) analysis. Bioadhesion force, measured with TAXT2i texture analyzer, showed that the wafers had a good bioadhesive property which could be advantageous for retaining the drug into the buccal cavity. Conclusion. The observed responses taken were in agreement with the experimental values, and Loratadine wafers were produced with less experimental trials, and a patient compliant product was achieved with the concept of formulation by design.

show abstract

The relative bioavailability of loratadine administered as a chewing gum formulation in healthy volunteers

Cited by 17 publications

References 10 publications

Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives

Measurement of xenobiotics in saliva: is saliva an attractive alternative matrix? Case studies and analytical perspectives

Comparative study on the predictability of statistical models (RSM and ANN) on the behavior of optimized buccoadhesive wafers containing Loratadine and their in vivo assessment

Design Expert Supported Mathematical Optimization and Predictability Study of Buccoadhesive Pharmaceutical Wafers of Loratadine

Contact Info

Product

Resources

About